AGILeBiotics entered successfully the Health-i-Care program (INTERREG) starting a collaboration with the University Medical Center Groningen (UMCG) and Hospitals in Germany (Muenster and Oldenburg). Health-i-Care is focusing on the development of innovative products and technologies to protect the society from infections caused by resistant microorganisms and to limit the spread of multidrug-resistant bacteria. Thanks to our participation in the Health-i-Care program, AGILeBiotics has not only access to expert’s knowledge and support, but also receives non-dilutive funding accelerating our in-house antibiotic development against hospital-acquired multidrug-resistant infections.